Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (9): 1618-1621.doi: 10.3969/j.issn.1673-8225.2012.09.023

Previous Articles     Next Articles

Meta-analysis of rivaroxaban safety after total hip arthroplasty

Li Jun, Wang Jian, Shi Zhan-jun, Li Yang   

  1. Department of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou  510515, Guangdong Province, China
  • Received:2011-09-03 Revised:2011-10-27 Online:2012-02-26 Published:2012-02-26
  • Contact: Shi Zhan-jun, Professor, Doctoral supervisor, Department of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China zhanjunshi@yahoo.com.cn
  • About author:Li Jun☆, Studying for doctorate, Department of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China junliarmy@163.com

PDF

407

Cited

5

Abstract:

BACKGROUND: Many experiments have proved that rivaroxaban can prevent the venous thromboembolism after total hip arthroplasty, but its safety has not been confirmed.
OBJECTIVE: To systematically review the safety of rivaroxaban and enoxaparin for prevention of venous thromboembolism after total hip arthroplasty.
METHODS: We searched the documents about the safety of rivaroxaban and enoxaparin in the prevention of venous thromboembolism after total hip arthroplasty at home and abroad. Selected the literatures met evaluation criteria and made a Meta-analysis by RevMan 5.1 software.
RESULTS AND CONCLUSION: Six randomized controlled trials involving 9 611 patients were included in our Meta-analysis, five in English and one in Chinese. The results showed the incidence of major bleeding event of rivaroxaban was higher than that of enoxaparin after total hip arthroplasty, RR was 1.75 (95%CI, 0.76-4.04), Z=1.31(P=0.19); clinically relevant non-major bleeding incidence of rivaroxaban was higher than that of enoxaparin, RR was 1.29 (95%CI, 0.99-1.68), Z=1.85(P=0.06); the minor bleeding event incidence of rivaroxaban were lower than that of enoxaparin, RR was 0.98 (95%CI, 0.76-1.25), Z=0.20(P=0.84); total bleeding events incidence of rivaroxaban were higher than enoxaparin, RR was 1.13 (95%CI, 0.95-1.35), Z=1.38(P=0.17). The safety of rivaroxaban in the prevention of venous thromboembolism after total hip arthroplasty was corresponding to enoxaparin, and the difference was not significant.

CLC Number: